Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

Part of paid clinical trials in South Dartmouth, Massachusetts.

Sponsor
Advanced Eye Research Associates
Study ID
NCT03297684
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Accepted

Interventions

Study Details

To assess the biomarker profile in diabetic macular edema patients in response to intravitreal aflibercept injection. Patients with diabetic macular edema who meet study requirements will receive monthly intravitreal injections of aflibercept as approved by FDA for a period of 6 months. A small quantity of fluid will be removed from the vitreous at each injection for laboratory evaluation of biomarkers present before, during and after treatment with aflibercept.

Key Dates

Start date
Apr 11, 2018
Status verified
Feb 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
40 participants (estimated)

Primary Outcome Measure

Measure biomarkers in aqueous humor from individuals with DME [ Time Frame: 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Advanced Eye CentersSouth DartmouthMassachusetts02747-

Find similar trials in South Dartmouth, MA

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
Advanced Eye Centers· South Dartmouth, MA

Related Studies